Wednesday, July 9, 2008
Glaxo Sheds Early Drugs That Don’t Fit In
Pharma giant GlaxoSmithKline, forged in the wave of mega mergers that swept the industry over the past decade, is looking to slim down a little now. CEO Andrew Witty tells the Health Blog he is considering spinning off into a separate company some early-stage drugs that don’t fit disease areas he wants Glaxo to focus [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment